Imagion Biosystems

Imagion Biosystems EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Imagion Biosystems (IBX.AX) as of Oct 18, 2026 is -3.53 M AUD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -364,453.00 AUD — a change of 867.51% (lower).

EBITDA

-3.53 MAUD

YoY

867.51%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Imagion Biosystems is 2025 -3.53 M AUD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Imagion Biosystems was 2024 -364,453.00 AUD. It decreases by 867.51% lower compared to the previous year.

The Imagion Biosystems EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-8.12 M AUD
Jan 1, 2019
-3.28 M AUD
Jan 1, 2020
-7.40 M AUD
Jan 1, 2021
-7.91 M AUD
Jan 1, 2022
-11.03 M AUD
Jan 1, 2023
-13.77 M AUD
Jan 1, 2024
-364,453.00 AUD
Jan 1, 2025
-3.53 M AUD
The Imagion Biosystems EBITDA history
YEAREBITDAYoY
-3.53 MAUD+867.51%
-364,453.00AUD-97.35%
-13.77 MAUD+24.85%
-11.03 MAUD+39.39%
-7.91 MAUD+6.92%
-7.40 MAUD+125.47%
-3.28 MAUD-59.58%
-8.12 MAUD+22.04%
-6.65 MAUD+1,120.72%
-544,970.00AUD-86.79%
-4.12 MAUD+77.84%
-2.32 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Imagion Biosystems Stock analysis

What does Imagion Biosystems do? Imagion Biosystems Ltd is a Melbourne-based company operating in the Health Care sector. It focuses on research and development of non-radioactive diagnostic imaging technology. The company went public on June 22, 2017. Its MagSense technology uses bio-safe magnetic nanoparticles for cancer detection, specifically formulated for breast, prostate, and ovarian cancers. MagSense nanoparticles are injectable solutions tailored to each cancer type. The firm also develops PrecisionMRX nanoparticles for magnetic relaxometry, available in various coatings including dextran, mPEG, oleic acid, and carboxylic acid functionalized. Imagion Biosystems operates through a Research and Development segment. Imagion Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imagion Biosystems stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Imagion Biosystems is -3.53 M AUD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Imagion Biosystems changed from -364,453.00 AUD to -3.53 M AUD, representing a 867.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Imagion Biosystems since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Imagion Biosystems historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Imagion Biosystems

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Imagion Biosystems